In this text we will address Corydaline, a topic of great relevance and interest today. _Var1 has captured the attention of specialists, academics and the general public due to its impact on various aspects of daily life. Over the last few decades, Corydaline has experienced a notable increase in its importance, becoming a subject of study and research in fields as diverse as medicine, technology, economics and culture. In this article, we will delve into the various aspects related to Corydaline, exploring its origin, evolution, impact and future prospects. Through detailed analysis, we will seek to shed light on this topic to better understand its scope and meaning in contemporary society.
![]() | |
Names | |
---|---|
IUPAC name
2,3,9,10-Tetramethoxy-13α-methyl-13aβ-berbine
| |
Systematic IUPAC name
(13S,13aR)-2,3,9,10-Tetramethoxy-13-methyl-5,8,13,13a-tetrahydro-6H-isoquinolinoisoquinoline | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H27NO4 | |
Molar mass | 369.461 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
|
Corydaline is an acetylcholinesterase inhibitor isolated from Corydalis yanhusuo.[1]
Corydaline is a pharmacologically active isoquinoline alkaloid isolated from Corydalis tubers. It also has diverse biological activities. It exhibits the antiacetylcholinesterase(AChE; IC50 = 15 μM),[2] antiallergic, antinociceptive, and gastric emptying activities.
Corydaline exhibited strong nematocidal activity, showed little cytotoxicity and represents a potential treatment for Strongyloidiasis. Corydaline is nematocidal against S. ratti and S. venezuelensis third instar larvae with 50% paralysis (PC50) values of 18 and 30 μM, respectively.[3]
Corydaline exhibits gastrointestinal modulatory, antinociceptive, anti-allergic, and anti-parasitic activities. Corydaline (1 and 3 mg/kg) increases gastric emptying in rat models of apomorphine- and laparotomy-induced delayed gastric emptying.[4] Corydaline is currently in clinical trials as a potential treatment for functional dyspepsia.
In animal models, corydaline increases gastric emptying and small intestine transit speed and induces gastric relaxation.
In other animal models, corydaline inhibits chemically induced pain. Additionally, this compound may inhibit mast cell-dependent smooth muscle contraction of the aorta.
It inhibits thrombin-induced platelet aggregation in vitro (IC50 = 54.16 μg/ml).[5]